<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299308</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00142140</org_study_id>
    <secondary_id>1R01AG062548-01A1</secondary_id>
    <nct_id>NCT04299308</nct_id>
  </id_info>
  <brief_title>Acute Exercise and the Cerebral Metabolic Response in Aging and Alzheimer's Disease</brief_title>
  <acronym>AEROBIC</acronym>
  <official_title>Acute Exercise Response On Brain Imaging and Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal is to characterize the acute exercise response as it relates to brain&#xD;
      glucose metabolism in aging and Alzheimer's Disease (AD). The study team will also examine&#xD;
      lactate metabolism, relationships with cognition, and the effect of exercise intensity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: Compare the effects of acute, moderate intensity and acute, higher intensity exercise&#xD;
      on cerebral glucose metabolism in nondemented (ND) elderly and AD subjects. ND (n=30) and AD&#xD;
      (n=30) subjects will undergo a single bout of moderate intensity (45-55% HRR) or higher&#xD;
      intensity (65-75% HRR) exercise to assess the effect of exercise intensity on acute change in&#xD;
      brain glucose metabolism (rest to exercise). Investigators hypothesize that both moderate and&#xD;
      high intensity exercise will elicit a drop in global brain glucose metabolism compared to&#xD;
      quiet rest, but that the effect will be greater with higher intensity vs. moderate intensity&#xD;
      exercise, and greater in ND subjects than in AD subjects.&#xD;
&#xD;
      Aim 2: Characterize the effect of both exercise intensities on acute biomarker response and&#xD;
      cognition (memory and executive function) in ND and AD subjects. The acute biomarker response&#xD;
      to exercise and the effect on cognition has not been examined in aged or AD cohorts.&#xD;
      Investigators hypothesize that acute higher intensity exercise will elicit a greater blood&#xD;
      lactate response (area under the curve, AUC) compared to acute moderate intensity exercise,&#xD;
      and that this response will be greater in ND than in AD subjects. Investigators further&#xD;
      hypothesize that lactate AUC will track negatively with change in cerebral glucose metabolism&#xD;
      and cognitive performance. Although investigators will focus on lactate, they will also&#xD;
      quantify additional exercise-related biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 arm, cross-sectional</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorodeoxyglucose (FDG) positron emission tomography (PET) Metabolism (Standard Uptake Value Ratio)</measure>
    <time_frame>Resting Vs acute exercise bout: ~1 month</time_frame>
    <description>FDG PET measures reflecting cerebral metabolism standardized to the uptake value of the cerebellum and standardized uptake value ratios (SUVR) will be calculated from native-space region of interest (ROI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate Area Under the Curve</measure>
    <time_frame>Resting Vs acute exercise bout: ~1 month</time_frame>
    <description>Change in circulating lactate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor (BDNF) Change</measure>
    <time_frame>Resting Vs acute exercise bout: ~1 month</time_frame>
    <description>Change in circulating Brain Derived Neurotrophic Factor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Aging</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Moderate Intensity Aerobic Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45-55% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.45 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.55 + Resting HR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Aerobic Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>65-75% of heart rat reserve (HHR) Low range = ((Max HR from Visit 1) - Resting HR ) * 0.65 + Resting HR High range = ((Max HR from Visit 1) - Resting HR) * 0.75 + Resting HR</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Aerobic Exercise</intervention_name>
    <description>Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload</description>
    <arm_group_label>High Intensity Aerobic Exercise</arm_group_label>
    <arm_group_label>Moderate Intensity Aerobic Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 60 and older&#xD;
&#xD;
          -  Stable medication doses (&gt;1month)&#xD;
&#xD;
          -  Post-menopausal&#xD;
&#xD;
          -  Diagnosis of either Nondemented (CDR 0) or Probable AD (CDR 0.5 or 1 only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide consent&#xD;
&#xD;
          -  Diagnosis of insulin-dependent (Type 1) Diabetes Mellitus&#xD;
&#xD;
          -  Recent ischemic heart disease (&lt;2 years)&#xD;
&#xD;
          -  Diagnosis of an clinically significant chronic disease including cardiovascular&#xD;
             disease (CVD), other metabolic diseases (e.g., thyroid), cancer, human&#xD;
             immunodeficiency virus (HIV), or acquired immunodeficiency syndrome&#xD;
&#xD;
          -  Excluded from or unable to complete an MRI scan&#xD;
&#xD;
          -  Any Neurological disorders that have the potential to impair cognition or brain&#xD;
             metabolism (e.g., Parkinson's disease, stroke defined as a clinical episode with&#xD;
             neuroimaging evidence in an appropriate area to explain the symptoms).&#xD;
&#xD;
          -  Clinically significant depressive symptoms that may impair cognition, abnormalities in&#xD;
             B12, rapid plasma regain (RPR), or thyroid function that may impair cognition, use of&#xD;
             psychoactive and investigational medications, and significant visual or auditory&#xD;
             impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill Morris</last_name>
    <phone>913-945-7675</phone>
    <email>jmorris2@kumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Casey John</last_name>
    <phone>913-945-7672</phone>
    <email>cjohn@kumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univeristy of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Morris</last_name>
      <phone>913-945-7675</phone>
      <email>morrisj2@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>November 1, 2022</last_update_submitted>
  <last_update_submitted_qc>November 1, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

